GSK (GLAXF) Stock Analysis & Winston Score

GSK plc is a British pharmaceutical company that makes medicines and vaccines sold to patients, hospitals, and governments around the world. Its key products include HIV treatments (through its ViiV Healthcare unit), respiratory drugs like Nucala, and vaccines for diseases like shingles (Shingrix) and meningitis. GSK is one of the largest drugmakers in the world and is a leader in the HIV treatment market. GSK earns money by selling prescription medicines and vaccines to healthcare systems, pharmacies, and clinics globally. It operates across more than 100 countries, with major revenue coming from the US, Europe, and international markets. Its competitive edge comes from a deep pipeline of specialty medicines and a strong vaccines portfolio, which are harder to copy than standard drugs. The biggest risk GSK faces is patent expiration on key products, which allows cheaper generic competitors to enter the market and cut into revenue.